Aspen Neuroscience Featured in the Wall Street Journal

Aspen Neuroscience is excited to be featured, and very proud of the progress we’ve made to advance the science. Thank you to the Wall Street Journal for providing focus to iPSCs.

The article can be found here: https://www.wsj.com/articles/stem-cells-parkinsons-disease-heart-failure-60e9e21f?st=noc464icymdkvso&reflink=desktopwebshare_permalink

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.